Tripterygium in dermatologic therapy.
D000818:Animals; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001168:Arthritis / Q000188:drug therapy; D001528:Behcet Syndrome / Q000188:drug therapy; D003872:Dermatitis / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D004892:Erythema Multiforme / Q000188:drug therapy; D004893:Erythema Nodosum / Q000188:drug therapy; D006168:Guinea Pigs; D006801:Humans; D007165:Immunosuppression Therapy; D007918:Leprosy / Q000188:drug therapy; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D051379:Mice; D010936:Plant Extracts / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D010946:Plants, Medicinal; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D013281:Stomatitis, Aphthous / Q000188:drug therapy; D029757:Tripterygium; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D010936:Plant Extracts